New pill shows promise for tough lung cancer
Disease control
Not yet recruiting
This study tests a new pill, BPI-361175, for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations) and has stopped responding to standard treatments. The trial has three parts to find the best dose and check if the drug is safe and wor…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC